APA

Waddington C., Andrews N., Hoschler K., Walker W., Oeser C., Reiner A., John T., Wilkins S., Casey M., Eccleston P., Allen R., Okike I., Ladhani S., Sheasby E., Waight P., Collinson A., Heath P., Finn A., Faust S., Snape M., Miller E. & Pollard A. (20110207). Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. : Health technology assessment (Winchester, England).

Chicago

Waddington Cs, Andrews N, Hoschler K, Walker Wt, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston Pe, Allen Rj, Okike I, Ladhani S, Sheasby E, Waight P, Collinson Ac, Heath Pt, Finn A, Faust Sn, Snape Md, Miller E and Pollard Aj. 20110207. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. : Health technology assessment (Winchester, England).

Harvard

Waddington C., Andrews N., Hoschler K., Walker W., Oeser C., Reiner A., John T., Wilkins S., Casey M., Eccleston P., Allen R., Okike I., Ladhani S., Sheasby E., Waight P., Collinson A., Heath P., Finn A., Faust S., Snape M., Miller E. and Pollard A. (20110207). Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. : Health technology assessment (Winchester, England).

MLA

Waddington Cs, Andrews N, Hoschler K, Walker Wt, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston Pe, Allen Rj, Okike I, Ladhani S, Sheasby E, Waight P, Collinson Ac, Heath Pt, Finn A, Faust Sn, Snape Md, Miller E and Pollard Aj. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. : Health technology assessment (Winchester, England). 20110207.